Dark

Check out our Level2View

CVAC
CureVac N.V.
stock NASDAQ

Inactive

Jan 5, 2026

4.66USD-0.214%(-0.01)1,147,736

Pre-market

0.00USD-100.000%(-4.67)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 21, 2022

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022 Benzinga

07:02AM EST B of A Securities Downgrades CureVac to Underperform, Lowers Price Target to $20 Benzinga

Jan 18, 2022

06:40AM EST JMP Securities Initiates Coverage On CureVac with Market Outperform Rating, Announces Price Target of $52 Benzinga

Jan 17, 2022

11:54AM EST CureVac Chief Technology Officer Announced Resignation to Pursue New Career outside Biotech Industry Benzinga

07:07AM EST CureVac Chief Technology Officer Mariola Fotin-Mleczek To Resign, Effective January 31, 2022 RTTNews

Jan 10, 2022

05:25AM EST CureVac Outlines Upcoming Catalysts For Vaccine Programs Benzinga

Jan 7, 2022

04:16PM EST CureVac Announces Co. Expects To Start A Phase 1 Clinical Trial Assessing CV2CoV In The First Quarter Of 2022; Expects To Start Assessing A Modified Second-generation COVID-19 mRNA Vaccine Candidate In A Phase 1 Trial In The Third Quarter Of 2022 Benzinga

Dec 9, 2021

08:41AM EST Direxion Launches mRNA ETF (MSGR) PR Newswire

Nov 18, 2021

04:22PM EST CureVac Q3 2021 Revenue 29.3M Benzinga

07:55AM EST The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings Benzinga

06:51AM EST CureVac: CV2CoV Shows Comparable Antibody Levels To RTTNews

06:28AM EST CureVac Publishes In Nature Preclinical Data Of Second-Generation COVID-19 Candidate, CV2CoV RTTNews

05:55AM EST CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine Benzinga

Nov 10, 2021

07:07AM EST CureVac Presents Data At SITC From Phase 1 Study Of Oncology Candidate CV8102 Showing Systemic Immune Response Benzinga

Oct 22, 2021

10:18AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 22, 2021 Benzinga

05:48AM EDT Deutsche Bank Initiates Coverage On CureVac with Hold Rating, Announces Price Target of $35 Benzinga

Oct 15, 2021

03:37PM EDT Why CureVac Shares Are Falling Benzinga

Oct 12, 2021

11:53AM EDT Shares of CureVac N.V. (CVAC) slipped nearly 7% on Tuesday morning after the company withdraws its first mRNA-based Covid vaccine from approval process. RTTNews

09:42AM EDT Why CureVac Shares Are Trading Lower Today Benzinga

07:37AM EDT CureVac To Withdraw First-generation COVID-19 Vaccine RTTNews

07:09AM EDT CureVac To Shift Focus Of Covid-19 Vaccine Development To Second-Generation mRNA Technology Benzinga

05:47AM EDT CureVac Granted U.S. Patent #11,141,476 'MERS coronavirus vaccine' Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 23, 2021

10:20AM EDT European Medicines Agency Says Received Some Important Data On CureVac COVID-19 Vaccine, Says Will Be In Better Position To Understand Aspects Such As Manufacturing By Year-End Benzinga

Sep 15, 2021

10:35AM EDT Breaking Down The Inflation Numbers Draws Attention To Oil Prices Benzinga

Sep 14, 2021

10:51AM EDT Shares of German biotechnology firm Curevac N.V (CVAC) are down 5 percent on Tuesday's trading on news of the company cancelling two manufacturing deals for its experimental COVID-19 vaccine. RTTNews

08:49AM EDT CureVac N.V. (CVAC), a German biopharmaceutical company, Tuesday said that it has decided to amend the long-term footprint of the external European manufacturing network for its messenger ribonucleic acid (mRNA) product pipeline. RTTNews

07:30AM EDT CureVac Announces Decision To Adjust Long-term Footprint Of External European Network For MRNA Product Pipeline RTTNews

07:19AM EDT CureVac Announces Contracts With WACKER And Celonic Terminated, Rentschler Biopharma And Novartis Unaffected; Says 'The decision was made in response to the reduced short-term peak demand for vaccines' Benzinga

Sep 9, 2021

07:27AM EDT EMA Head Of Vaccines Strategy Cavaleri Says Decision On CureVac COVID-19 Vaccine Expected In Coming Weeks Benzinga

Aug 31, 2021

07:19AM EDT CureVac Publishes CVnCoV Phase 2b/3 Study Data In Preprints With The Lancet RTTNews

07:12AM EDT Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot Benzinga

07:04AM EDT CureVac's Cvncov Phase 2B/3 Study Data Of CVnCoV Published In Preprints With The Lancet; Significant Protection Was Demonstrated, Protection Against Moderate To Severe Disease For This Age Group Was 77%, 100% Protection Against Hospitalization Or Death Benzinga

Aug 30, 2021

08:37AM EDT CureVac Preclinical Data Demonstrates Significant Reduction Of Liver Fibrosis With MRNA Therapeutic RTTNews

07:07AM EDT CureVac Highlights Publication In Journal Of Hepatology Demonstrating 'Significant Reduction of Liver Fibrosis with mRNA Therapeutic' Benzinga

Aug 16, 2021

04:08PM EDT Boehringer Ingelheim Scraps Lung Cancer Program With CureVac Benzinga

10:42AM EDT CureVac Q2 Sales 22.4M, Down From Benzinga

10:11AM EDT Shares of CureVac N.V. (CVAC) are currently trading at $60.02, up $1.22 or 2.07%, with trading volume of over 518K versus an average volume of 1.27 million shares. The stock has been trading in the range of $43.00 - $151.80 for the past one year. RTTNews

08:12AM EDT CureVac Says COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response In Preclinical Study RTTNews

08:10AM EDT CureVac Q2 Pre-tax Losses EUR 152.2 Mln Vs Loss EUR 12.0 Mln Last Year RTTNews

07:12AM EDT Curevac And GSK Announce Second-Generation MRNA COVID-19 Vaccine Candidate, Cv2Cov, Demonstrates Improved Immune Response And Protection In Preclinical Study Benzinga

07:02AM EDT Curevac Announces Second-Generation MRNA COVID-19 Vaccine Candidate, Cv2Cov, Demonstrates Improved Immune Response And Protection In Preclinical Study Benzinga

Jul 21, 2021

04:56AM EDT Novartis CFO Said Co to Deliver 50M CureVac COVID-19 Vaccines this Year Benzinga

Jul 20, 2021

02:32PM EDT EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine Benzinga

Jul 6, 2021

02:24PM EDT South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters Benzinga

Jul 1, 2021

08:28AM EDT EU Drug Regulator Says It Will Proceed With Evaluating CureVac Clinical Data For COVID-19 Vaccine Benzinga

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

07:27AM EDT Curevac CEO Said Earlier on Thursday, Company Was in Talks With EU Regarding its Covid Vaccine; Said Aiming to Produce 200M to 300M Doses This Year Benzinga

06:14AM EDT A Peek Into The Markets: US Stock Futures Up Ahead Of Initial Jobless Claims Data Benzinga

Jun 30, 2021

05:38PM EDT CureVac Covid Vaccine Records 48% Efficacy In Final RTTNews

05:17PM EDT CureVac Announces Results From Final Analysis Of Its Phase 2b/3 Study Of COVID-19 Vaccine Candidate CVnCoV RTTNews

04:39PM EDT CureVac Says Trial Showed Vaccine Efficacy Of 48% Against COVID-19 Of Any Severity Across All Age Groups And 15 Variants Benzinga

04:38PM EDT CureVac Reports Data From Phase 2b/3 Trial Of COVID-19 Vaccine; Showed Efficacy Of 53% Against Disease Of Any Severity, Efficacy Of 77% Against Moderate And Severe Disease, Full Protection Against Hospitalization Or Death Benzinga

04:33PM EDT CureVac Says Final Data From Phase 2B/3 Trial Of COVID-19 Vaccine Candidate, Demonstrates Protection In Age Group Of 18 - 60, Statistical Success Criteria For Primary Endpoint Met On Basis Of 228 Adjudicated Cases Benzinga

11:18AM EDT Why Shares Of CureVac Are Trading Higher On Wednesday Benzinga

07:43AM EDT CureVac N.V. (CVAC) said that it has appointed Malte Greune as Chief Operating Officer effective July 1, 2021. RTTNews

07:15AM EDT CureVac Announces Appointment Of Dr. Malte Greune As Chief Operating Officer And Transition Of Dr. Florian von der Mlbe To Lead Accelerated Development Of The RNA Printer Benzinga

Jun 23, 2021

07:54AM EDT Biopharmaceutical company CureVac N.V. (CVAC) announced that Ingmar Hoerr, former Founding-CEO and former member of the Supervisory Board of CureVac, has withdrawn his candidacy for nomination to the Supervisory Board. RTTNews

07:42AM EDT CureVac: Ingmar Hoerr Withdrawn His Candidacy For Nomination To Supervisory Board RTTNews

Jun 22, 2021

10:57AM EDT Europe Purchases Additional 150M Doses Of Moderna COVID-19 Vaccine Benzinga

Jun 21, 2021

06:41AM EDT German Financial Watchdog Investigates Possible Insider Trading In Curevac Shares Benzinga

Jun 18, 2021

02:14AM EDT Tesla Partner CureVac Says Will Find 'Sweet Spot' For COVID-19 Vaccine Despite Disappointing Data Benzinga

Jun 17, 2021

02:33PM EDT Mid-Afternoon Market Update: Nasdaq Gains Over 100 Points; CureVac Shares Plummet Benzinga

12:09PM EDT Mid-Day Market Update: Gold Drops Over 4%; Midatech Pharma Shares Jump Benzinga

10:13AM EDT Mid-Morning Market Update: Markets Mixed; Kroger Earnings Top Views Benzinga

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 17, 2021 Benzinga

09:21AM EDT B of A Securities Downgrades CureVac to Neutral, Announces $50 Price Target Benzinga

08:33AM EDT The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme Benzinga

08:10AM EDT From CureVac Webcast To Discuss Phase 2b/3 Trial Of Its COVID-19 Vaccine Candidate: CEO Says Its Study Is 'Unmatched' In Its Geographic Footprint, Study Enrolled 40K Participants In 10 Countries Benzinga

05:07AM EDT Tesla-Backed CureVac Plunges On Underwhelming COVID-19 Vaccine Efficacy Data Benzinga

Jun 16, 2021

05:42PM EDT Shares of biotechnology company CureVac NV (CVAC) are down 50 percent on Wednesday's after-trade after the company said that its trial COVID-19 vaccine showed an efficacy of 47% against the illness. RTTNews

05:02PM EDT CureVac Issues PR Confirming Earlier News Co's COVID-19 Vaccine Demonstrated An Interim Vaccine Efficacy Of 47% Against COVID-19 Disease Of Any Severity And Did Not Meet Prespecified Statistical Success Criteria Benzinga

04:57PM EDT Watching Tesla Shares; Traders Circulate April Bloomberg Report Titled 'Musk Deletes Tweet Speculating on CureVac's Vaccine Approval' Benzinga

04:47PM EDT CureVac Says COVID-19 Vaccine Demonstrated An Interim Vaccine Efficacy Of 47% Against COVID-19 Disease Of Any Severity And Did Not Meet Prespecified Statistical Success Criteria Benzinga

04:45PM EDT CureVac Provides Update On Phase 2b/3 Trial Of First-Generation COVID-19 Vaccine Candidate, CVnCoV Benzinga

Jun 9, 2021

01:56PM EDT CureVac Shares Fall To Session Low; Evercore ISI Says Spoke With Co. Mgmt., Is Categorically Denying Report EMA Doesn't See Approval For COVID-19 Vaccine Before Aug., Says Newspaper Misquoted Co. Benzinga

Jun 8, 2021

11:00AM EDT Shares of German biopharmaceutical company CureVac N.V. (CVAC) are down 13 percent on Tuesday's trading on reports that the European Medicines Agency will not take a decision on the approval of the company's COVID-19 vaccine before August. RTTNews

10:19AM EDT Mid-Morning Market Update: Markets Mixed; Thor Industries Beats Q3 Estimates Benzinga

Jun 2, 2021

07:32AM EDT CureVac Appoints Klaus Edvardsen As Chief Development Officer RTTNews

Jun 1, 2021

08:11AM EDT CureVac's COVID-19 Vaccine Is Safe, But Efficacy Not Yet Disclosed Benzinga

May 29, 2021

12:40AM EDT CureVac N.V. (CVAC) said that the independent Data Safety Monitoring Board or DSMB has confirmed that the pivotal Phase 2b/3 study, dubbed as HERALD, for the company's first-generation COVID-19 vaccine candidate, CVnCoV, has passed a first interim analysis at 59 adjudicated COVID-19 cases. RTTNews

May 28, 2021

04:46PM EDT CureVac Announces It's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation Benzinga

May 26, 2021

07:45AM EDT Biopharmaceutical company CureVac N.V. (CVAC) reported Wednesday a pre-tax loss of 112.2 million euros for the first quarter of 2021, sharply wider than a pre-tax loss of 23.9 million euros in the prior-year quarter. RTTNews

07:45AM EDT CureVac Q1 Operating Loss 115.8M Benzinga

07:18AM EDT CureVac Q1 Revenue EUR 10.0 Mln Vs EUR 3.1 Mln Last Year RTTNews

May 13, 2021

08:25AM EDT Biopharmaceutical company CureVac N.V. (CVAC) announced Thursday that its second generation COVID-19 vaccine candidate, CvnCoV, demonstrated high immunogenicity against virus variants in preclinical study. The first clinical trials for CV2CoV are expected to start in the third quarter of 2021. RTTNews

07:39AM EDT CureVac: CV2CoV Demonstrates High Immunogenicity Against Virus Variants In Preclinical Study RTTNews

07:34AM EDT CureVac COVID-19 Vaccine Candidate, CV2CoV, Demonstrates High Immunogenicity Against Virus Variants In Preclinical Study Benzinga

Apr 26, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021 Benzinga

07:28AM EDT Guggenheim Initiates Coverage On CureVac with Buy Rating Benzinga

Apr 19, 2021

07:48AM EDT CureVac Swiss AG Begins Rolling Submission Process For CVnCoV With Swissmedic RTTNews

07:02AM EDT CureVac Swiss AG Initiates Rolling Submission Process For mRNA-Based COVID-19 Vaccine Candidate, Cvncov, With Swissmedic Benzinga

Apr 15, 2021

08:38AM EDT CureVac Posts Wider Loss In Q4 RTTNews

07:49AM EDT CureVac Reports Q4 Sales 6.0M Down From Benzinga

07:39AM EDT CureVac Now Expect Completing Data Submission To File For Conditional Approval Of CVnCoV In Q2'21 RTTNews

07:36AM EDT CureVac Says Pivotal Phase 2B/3 In Europe And Latin America Fully Recruited With Over 40,000 Participants, Interim Analysis For Efficacy Expected In Q2 2021; Reiterates Expects To Manufacture Up To 300M Doses Of CVnCoV By End Of 2021 And Up To 1B In 2022 Benzinga

07:34AM EDT CureVac Says CVnCoV Vaccine Believed To Be On Track To Provide Data For Conditional Approval Based On EMA Rolling Submission; Says Pivotal Phase 2B/3 In Europe And Latin America Fully Recruited With Over 40,000 Participants Benzinga

04:13AM EDT Earnings Scheduled For April 15, 2021 Benzinga

Apr 14, 2021

09:13AM EDT UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots Benzinga

Apr 12, 2021

02:43PM EDT South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report Benzinga

Apr 8, 2021

12:38PM EDT Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC Benzinga

Apr 7, 2021

11:16AM EDT Europe's Drug Watchdog Concludes Possible Link Between AstraZeneca COVID-19 Vaccine And Blood Clots Benzinga

Mar 31, 2021

02:27PM EDT EMA May Issue Updated Recommendation If AstraZeneca Jab-Clot Link Is Established: Report Benzinga

07:09AM EDT Pfizer-BioNTech's COVID-19 Vaccine Gives 100% Protection In Adolescents Benzinga

Mar 30, 2021

09:27AM EDT CureVac Taps Celonic For COVID-19 Vaccine Production Benzinga

07:34AM EDT Celonic And CureVac Announce Agreement To Manufacture Over 100 Million Doses Of CureVac's COVID-19 Vaccine Candidate, CVnCoV Benzinga

Mar 29, 2021

07:23AM EDT White House Contemplates Waiving-Off Patent Protections For COVID-19 Treatments Benzinga

Mar 26, 2021

12:42PM EDT GlaxoSmithKline, Vir Biotechnology Seek Emergency FDA Authorization For COVID-19 Drug Benzinga

Mar 23, 2021

09:14AM EDT CureVac N.V. (CVAC) published preclinical data showing that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 or the South African variant, and a strain of the original SARS-CoV-2 B1 lineage in a transgenic mouse model. RTTNews

08:46AM EDT CureVac's CVnCoV Demonstrates Protection Against SARS-CoV-2 B.1.351 Variant In Preclinical Challenge Study RTTNews

08:08AM EDT CureVac Says CVnCoV COVID-19 Vaccine Candidate Demonstrated Protection Against South Africa Variant In Challenge Study Benzinga

Mar 22, 2021

10:15AM EDT CureVac Expands Late-Stage Trials Of COVID-19 Vaccine Candidate Benzinga

08:43AM EDT CureVac N.V. (CVAC) said Monday that it plans to expand and further specify the protocols of its ongoing late-stage clinical trials with its COVID-19 vaccine candidate, CvnCoV. RTTNews

08:22AM EDT CureVac Plans To Expand, Specify Protocols Of Ongoing Late-stage Clinical Trials With CVnCoV RTTNews

08:17AM EDT CureVac Confirms Co Expanding CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses To Include Phase 2b/3 Variant Specification And Efficacy Secondary Endpoint To Phase 2a Benzinga

08:08AM EDT CureVac Reports Expansion Of CvnCoV COVID-19 Vaccine Candidate Trial Analyses To Include Phase 2b/3 Variant Specific, Efficacy Secondary Endpoint To Phase 2a Benzinga

06:11AM EDT AstraZeneca's COVID-19 Shot Shows 79% Efficacy In US Trials Benzinga

Mar 17, 2021

12:40PM EDT Pfizer/BioNTech COVID-19 Vaccination Could Protect Pregnant Women, Newborns, Study In Israel Suggests: Reuters Benzinga

Mar 15, 2021

02:11PM EDT Germany, France Join List Of Countries Suspending AZN's COVID-19 Vaccine; WHO Urges Not To Halt Vaccinations Benzinga

Mar 10, 2021

05:47AM EST Pfizer, BioNTech Predict Increase In Capacity To 3B COVID-19 Vaccine Shots In 2022: Bloomberg Benzinga

Mar 5, 2021

09:01AM EST WHO, SII Warn Of Raw Materials Shortage For COVID-19 Shots, Cites US Law As 'Serious' Limit:' Bloomberg Benzinga

Mar 4, 2021

08:37AM EST CureVac Spokesman Says Co. Now Expects Initial Results From Phase 2B/3 COVID-19 Vaccine Study In Early Q2; Says Aiming To Have Critical Number Of Infections With Different Variants In Trial To Have Statistically Significant Read-Out For Certain Variants Benzinga

08:37AM EST Novartis Lends Support To Manufacture CureVac's COVID-19 Shots Benzinga

07:30AM EST CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV Benzinga

07:04AM EST CureVac, Novartis Sign Initial Agreement On Manufacturing Of COVID-19 Vaccine Candidate, CVnCoV RTTNews

06:08AM EST Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says Benzinga

Mar 3, 2021

07:13AM EST EU Considers Emergency Approvals To Boost COVID-19 Vaccine Rollout: Reuters Benzinga

Mar 2, 2021

12:26PM EST European Officials Seek To Garner Support For AstraZeneca COVID-19 Shot: CNBC Benzinga

09:13AM EST Merck To Offer Hand With JNJ COVID-19 Vaccine Production, Biden Administration Says: Report Benzinga

08:45AM EST People Allergic To Pfizer, Moderna COVID-19 Vaccine Might Be Allowed To Get JNJ Shot: CNBC Benzinga

05:51AM EST AstraZeneca, Pfizer/BioNtech Single Shot COVID-19 Jab 80% Effective At Preventing Hospitalizations In Elderly Benzinga

05:15AM EST Novavax Bullish On Potential FDA EUA Nod For COVID-19 Vaccine By May Benzinga

Feb 26, 2021

07:17AM EST Johnson & Johnson's COVID-19 Vaccine Likely To Get EU Approval Early March: Bloomberg Benzinga

Feb 25, 2021

05:50AM EST Moderna Raises 2021 Base COVID-19 Vaccine Production Plan To 700M Doses Benzinga

05:42AM EST Moderna To Test New COVID-19 Vaccine Targeting South Africa Strain Benzinga

Feb 23, 2021

06:40AM EST FDA Says Conduct Smaller Trials To Test Vaccine Efficacy Against COVID Variants Benzinga

Feb 22, 2021

07:14AM EST Sanofi/GlaxoSmithKline Initiate COVID-19 Vaccine Development After Setback Benzinga

Feb 18, 2021

07:26AM EST Pfizer Says South African Variant Could Significantly Reduce Vaccine Protection: Reuters Benzinga

Feb 17, 2021

06:46AM EST Shortage Of Giant Sterile Liners Threatens Global Vaccines Rollout: FT Benzinga

Feb 12, 2021

11:28AM EST COVID-19 Vaccine Updates: US Strikes 100M-Dose Supply Deals With Moderna, Pfizer, EU Starts Rolling Review Of CureVac Vaccine Benzinga

Feb 5, 2021

11:02AM EST CureVac Shares Gain After UK Backs Company's Vaccine Development Efforts For COVID-19 Variants Benzinga

08:43AM EST CureVac N.V. (CVAC) said Friday that it has collaborated with the UK Government to develop and manufacture potential vaccine candidates against SARS-CoV-2 variants. RTTNews

07:18AM EST CureVac Confirms Earlier Report; Says Co And UK Government To Collaborate On Development Of Vaccines Against COVID-19 Variants (See Previous Headlines) Benzinga

07:03AM EST UPDATE: CureVac Expected To Supply 50M Doses Of Variant Vaccines To UK, Subject To Regulatory Approval Benzinga

07:02AM EST CureVac 6-K Shows Co. Entered Collab With UK Gov't. To Develop, Manufacture Potential Vaccine Candidates Against SARS-CoV-2 Variants, No Terms Disclosed Benzinga

Feb 4, 2021

11:09AM EST CureVac Expands Early-Stage Study Evaluating CV8102 In Skin Cancer Benzinga

07:39AM EST CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma Benzinga

Feb 3, 2021

11:43AM EST GlaxoSmithKline Shares Slip On Weaker Profit Forecast For 2021, Plans To Cut Dividend Benzinga

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

06:12AM EST A Peek Into The Markets: US Stock Futures Up; Alphabet, Amazon Report Upbeat Earnings Benzinga

05:15AM EST GlaxoSmithKline, CureVac In Pact To Develop Vaccines For COVID-19 Variants Benzinga

Feb 1, 2021

01:38PM EST German Chancellor Merkel Says Johnson & Johnson And CureVac Expected To Deliver Vaccine In Q2 2021 Benzinga

07:03AM EST CureVac And Rentschler Biopharma Ramp Up Manufacturing Of COVID-19 Vaccine, CVnCoV Benzinga

Jan 28, 2021

09:53AM EST Shares of biopharmaceutical company CureVac N.V. (CVAC) are falling more than 7% Thursday morning at $87.70. RTTNews

Jan 26, 2021

08:07AM EST The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market Benzinga

Jan 25, 2021

04:23PM EST CureVac Announces Proposed 5M Share Common Stock Offering Benzinga

Jan 22, 2021

10:37AM EST CureVac, Novavax Shares Quiet Following Report Mexican Foreign Minister Said Co.'s Will Commence Phase 3 Trials In Mexico for COVID-19 Vaccine Benzinga

Jan 11, 2021

07:02AM EST CureVac Says Its COVID-19 Vaccine Candidate, CVnCoV Demonstrated Efficient Protection Of Non-Human Primates During SARS-CoV-2 Challenge Infection Benzinga

Jan 8, 2021

09:51AM EST UPDATE: Health Ministry Official Says Germany Signed Preliminary Deal With CureVac In August For 20M Doses And With BioNTech For 30M Doses Benzinga

09:50AM EST German Health Ministry Documents Show Berlin Secured 50M Doses Of COVID-19 Vaccine From BioNTech And CureVac On Top Of EU Supplies Benzinga

Jan 7, 2021

10:06AM EST Shares of CureVac N.V. (CVAC) jumped 15% on Thursday morning after the German biotech company announced partnership with Bayer AG to develop coronavirus vaccine. RTTNews

08:13AM EST CureVac CEO Says We Certainly Shoot For The Same Level Of Efficacy That Has Been Shown In Trials Of Moderna, BioNTech-Pfizer Benzinga

08:00AM EST Curevac Ceo Says Interim Results Of Ongoing Covid-19 Vaccine Trial Expected End-Q1, Early Q2 Which Would Form Basis For Request For Approval Benzinga

06:29AM EST CureVac Announced Earlier, Co and Bayer Joining Forces on COVID-19 Vaccine Candidate CVnCoV; CureVac Shares Rise 16% Premarket Benzinga

Dec 24, 2020

12:14PM EST CureVac shares are trading higher. The company on Monday announced it would start a phase 3 trial for its COVID-19 vaccine candidate. Benzinga

Dec 17, 2020

10:29AM EST CureVac N.V. (CVAC) shares are down more than 8 percent on Thursday morning trade continuing its fall since December 7 as it is a bit behind the race for COVID-19 vaccine. RTTNews

Dec 14, 2020

06:22AM EST CureVac Announced Earlier Commencement of Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoV Benzinga

01:13AM EST CureVac N.V. (CVAC) has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The study is expected to include more than 35,000 participants at sites in Europe and Latin America. RTTNews

01:05AM EST CureVac Enrolls First Participant In Pivotal Phase 2b/3 Trial For COVID-19 Vaccine Candidate, CVnCoV RTTNews

Dec 11, 2020

10:06AM EST CureVac N.V. (CVAC) shares are declining on Friday morning trade, as the company is expecting results for its efficacy studies by first half of 2021 only. The company had recorded promising initial results. RTTNews

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

06:14AM EST Credit Suisse Downgrades CureVac to Underperform Benzinga

Dec 8, 2020

08:04AM EST The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings Benzinga

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 30, 2020

07:45AM EST CureVac Reports Q3 Sales 5.2M Up From Benzinga

04:11AM EST Earnings Scheduled For November 30, 2020 Benzinga

Nov 23, 2020

07:51AM EST CureVac N.V. (CVAC) and Wacker Chemie AG (WKCMY.PK, WKCMF.PK) said Monday they have signed a contract for the manufacture of CureVac's mRNA-based COVID-19 vaccine candidate, CVnCoV, at Wacker's biotech site in Amsterdam. RTTNews

07:06AM EST CureVac, WACKER Sign Manufacturing Contract For COVID-19 Vaccine Candidate CVnCoV RTTNews

Nov 20, 2020

07:12AM EST Pfizer, Moderna COVID-19 Vaccines Could Get Limited EU Approval Before Year-End: Report Benzinga

07:03AM EST BioNtech and Moderna Vaccines May Get Emergency Use Approval In Europe Benzinga

Nov 17, 2020

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

07:22AM EST CureVac Says Increasing Capacity To Reach Up To 300M Doses In 2021 And Up To 600M Doses In 2022 Benzinga

07:22AM EST CureVac Establishes European-Based Network To Ramp Up Manufacturing Of Its CVnCoV COVID-19 Vaccine Candidate Benzinga

Nov 16, 2020

01:17PM EST CureVac Confirms Earlier Reports That European Commission Will Authorize Agreement For Supply Of Up To 405M Doses of mRNA-Based COVID-19 Vaccine Candidate CVnCoV Benzinga

01:13PM EST CureVac 6-K Shows 'CureVac is currently expanding manufacturing capacities for the large-scale manufacturing of CVnCoV. Vaccine doses are expected to be produced both at CureVac's in-house, GMP-certified manufacturing site in Germany and across a broad European manufacturing network' Benzinga

01:12PM EST CureVac Says Vaccine Doses Are Expected To Be Produced At Co.'s In-House, GMP-Certified Manufacturing Site In Germany, Across Broad European Manufacturing Network Benzinga

10:02AM EST EU Commission President Says On Tuesday Commission Will Authorize Vaccine Deal With CureVac Benzinga

Nov 12, 2020

07:04AM EST CureVac COVID-19 Vaccine Candidate Suitable For Standard Fridge Temperature Logistics; Data For Covid-19 Vaccine Candidate Support At Least Three Months Of Stability At +5 C (+41 F), Up To 24 Hours Of Stability Established At Room Temperature Benzinga

05:43AM EST Curevac CEO Said Does Not Expect That Covid-19 Vaccination Will Have to Be Repeated Every Year; Said It Currently Does Not Look Like the Coronavirus Mutates as Much as the Seasonal Flu Benzinga

05:42AM EST Curevac CEO Said Plans to Be Able to Produce 300M-400M Covid-19 Vaccine Doses Next Year Benzinga

Nov 2, 2020

07:27AM EST CureVac Reports Interim Phase 1 Data For Its COVID-19 Vaccine Candidate, CVnCoV; Says Showed 'Balanced immune response with strong induction of binding,' Was Generally Well Tolerated. Says Data Support 12g Dose For Pivotal Phase 2b/3 Clinical Trial Benzinga

Oct 23, 2020

07:30AM EDT CureVac Reports Preclinical Data For Its Covid-19 Vaccine Candidate, CVnCoV; Showed 'Strong induction of antibody and T cell responses in animal models' And A 'Favorable safety profile with no evidence of vaccine-enhanced disease' Benzinga

07:26AM EDT CureVac Says Interim Phase 1 Data Is Expected To Be Announced Shortly Benzinga

07:25AM EDT CureVac Reports Preclinical Data For Its Covid-19 Vaccine Candidate, CVnCoV; Showed 'Strong induction of antibody and T cell responses in animal models'A nd A 'Favorable safety profile with no evidence of vaccine-enhanced disease' Benzinga

Oct 21, 2020

02:16PM EDT CureVac Option Alert: Jan 15 $60 Calls Sweep (42) near the Ask: 191 @ $3.708 vs 44 OI; Earnings 11/3 Before Open [est] Ref=$48.965 Benzinga

Oct 12, 2020

03:30PM EDT Q3 The Busiest Since 2014 For IPOs, Led By Unicorns, SPACs Benzinga

Oct 8, 2020

05:39AM EDT Curevac CTO Fotin-mleczek Says Hope to Have Trial Data on Immune Response to Covid-19 Vaccine Candidate by End of Month; Start Phase 2/3 Trial by the End of Year Benzinga

Sep 30, 2020

10:11AM EDT Shares of CureVac N.V. (CVAC) are gaining over 6% on Wednesday morning. Tuesday after the bell, CureVac announced that it has initiated phase 2a clinical trial of its COVID-19 vaccine candidate. RTTNews

06:31AM EDT A Peek Into The Markets: US Stock Futures Down Following Presidential Debate Benzinga

Sep 29, 2020

06:05PM EDT CureVac N.V. (CVAC) Tuesday announced that it has initiated phase 2a clinical trial of its COVID-19 vaccine candidate. RTTNews

05:40PM EDT Jiayin Group Inc. (JFIN) - Shares of the Chinese online financial marketplace surged over 30% on Tuesday after the bell. Jiayin Group said it has closed the acquisition of 35% equity interest in Keen Best Investment Ltd. from China Smartpay Group Holdings. RTTNews

04:13PM EDT CureVac Reports Initiation Of Phase 2a Trial Of COVID-19 Vaccine Candidate Benzinga

Sep 10, 2020

06:46AM EDT Elon Musk On Tesla's Approach To Innovation: Don't Play With The Same Old Chess Pieces Benzinga

Sep 8, 2020

01:04PM EDT B of A Securities Initiates Coverage On CureVac with Buy Rating, Announces Price Target of $70 Benzinga

10:10AM EDT Benzinga's Top Upgrades, Downgrades For September 8, 2020 Benzinga

06:38AM EDT Jefferies Initiates Coverage On CureVac with Hold Rating, Announces Price Target of $58 Benzinga

05:13AM EDT Credit Suisse Initiates Coverage On CureVac with Neutral Rating, Announces Price Target of $68 Benzinga

Sep 4, 2020

09:23AM EDT CureVac Confirms Earlier Report That Co To Receive Up To 252M From German Federal Ministry Of research For Further COVID-19 Vaccine Development, Production Capacity Expansion Benzinga

07:24AM EDT CureVac Has Received A Financial Injection Of 252M From The German Govt. For Accelerated Development And Production Of A Coronavirus Vaccine Benzinga

Aug 31, 2020

04:48AM EDT Elon Musk Heads To Germany To Assess Tesla Giga Berlin, Vaccine Printer Progress Benzinga

Aug 24, 2020

05:16PM EDT KfW Reports 65.8% Active Stake In CureVac Benzinga

10:56AM EDT CureVac Shares Move Slightly Higher; dievini Hopp BioTech holding Reports In 13D Filing A 44.8% Stake In Co Benzinga

Aug 20, 2020

06:51AM EDT CureVac shares are trading higher after the company announced it is in advanced discussions with the European Commission to supply up to 405 million doses of potential mRNA-based COVID-19 vaccines. Benzinga

06:16AM EDT CureVac and EC in Advanced Discussions to Supply up to 405M Doses of Potential mRNA-based COVID-19 Vaccine Benzinga

Aug 19, 2020

05:33AM EDT German Institute Says Coronavirus Vaccinations Could Start in Early 2021 Benzinga

Aug 17, 2020

10:16AM EDT Mid-Morning Market Update: Markets Mixed; JD.com Beats Q2 Views Benzinga

Aug 14, 2020

03:46PM EDT What To Know About The CureVac IPO Benzinga

12:19PM EDT CureVac Shares Open For Trade At $40; IPO Priced At $16/Share Benzinga

09:21AM EDT CureVac Shares Expected To Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $16/Share Benzinga

Share